Clinical Trials · NCT01194271
Neoadjuvant Ipilimumab in Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- M.D. Anderson Cancer Center
- Enrollment
- 19
- Start date
- Sep 2010
- Locations
- 1 site, United States
- Primary endpoint
- Immunologic Response: Number of Participants With Immune Response